Sacral Nerve Stimulation Market By Product (Devices, Accessories), By Application (Urinary and Fecal Incontinence, Chronic Anal Fissure, Others), By End User (Hospitals, Specialty Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Sacral Nerve Stimulation Market

The sacral nerve stimulation market is likely to experience a significant growth rate of 5.2% from 2023-2032 owing to increase in demand devices segment – .

A sacral nerve stimulator is a medical device that utilizes mild electrical impulses to modulate the sacral nerves, located near the base of the spine. It's employed to treat conditions like urinary and fecal incontinence, as well as pelvic pain and certain disorders affecting pelvic muscles. By regulating nerve signals, the stimulator can enhance control over bladder and bowel function while mitigating discomfort. Surgically implanted, it consists of a generator that emits controlled pulses to influence nerve activity, improving patients' quality of life by addressing these pelvic health issues.  

The growth of the sacral nerve stimulation market is primarily being propelled by the escalating prevalence of urological incontinence conditions, encompassing urinary and fecal incontinence, urge incontinence, and chronic anal fissure. These conditions collectively impact a substantial portion of the population, especially the elderly. Age-related factors such as muscle weakness, neurological disorders, and pelvic floor dysfunction significantly contribute to the surge in incontinence cases. 

For instance, according to Medscape report in 2023, urinary incontinence increases with age, affecting 38-55% of women older than 60 years and 50-84% of the elderly in long-term care facilities. Females experience a notably higher occurrence of urinary incontinence compared to males, attributed to factors like pregnancy, childbirth, menopause, and anatomical variations in pelvic structures. These specific physiological changes can lead to weakened pelvic floor muscles and compromised bladder control, elevating the vulnerability to urinary incontinence. 

The demand for sacral nerve stimulation devices is thus surging as they offer promising solutions to manage these challenging conditions. By directly influencing nerve signals, these devices provide targeted relief and improved control over bladder and bowel functions, enhancing the overall quality of life for affected individuals. As the prevalence of urological incontinence continues to rise, particularly among the aging population, the market for sacral nerve stimulation is expected to witness sustained growth due to its potential to address these pressing healthcare needs. 

Moreover, increased investment in healthcare infrastructure development is bolstering the growth of the sacral nerve stimulation market. As healthcare systems expand and modernize, there's a greater emphasis on advanced medical technologies like sacral nerve stimulators. This financial commitment facilitates improved accessibility to these devices and associated treatments, catering to the rising demand for effective solutions to urological incontinence and related conditions. 

Furthermore, the trend toward the adoption of implantable sacral nerve stimulation devices over traditional methods has played a crucial role in driving market growth. Traditional treatments often involve medications or non-invasive interventions that may not provide satisfactory outcomes for all patients. In contrast, implantable sacral nerve stimulators offer a more targeted and personalized approach. By directly modulating nerve signals, these devices can achieve more precise and sustainable results, making them an appealing choice for patients and healthcare providers alike. 

The sacral nerve stimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into devices and accessories. On the basis of application, it is categorized into urinary fecal incontinence, chronic anal fissure, and others (overactive bladder syndrome, urinary frequency). On the basis of end user, it is segregated into hospitals, specialty clinics, and others (research centers, ambulatory surgical centers). Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

The key players profiled in the study include Medtronic Plc, Beijing PINS Medical Co., Ltd., Saluda Medical Pty Ltd., and Axonics, Inc. The players in the market have been actively engaged in the adoption various strategies such as product launch, acquisition and product approval to remain competitive and gain advantage over the competitors in the market. For instance, in February 2021, Medtronic plc, a global leader in healthcare technology, received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of its InterStim II and InterStim Micro sacral neuromodulation (SNM) systems that use SureScan MRI leads. The updated MRI Guidelines allow for a wider range of MRI scan parameters and shorter wait time between MRI scans, thereby improving patient access to MRI exams and adding flexibility for MRI providers. 

Key Market Insights

By product type, the devices segment accounted for the largest share in terms of revenue in 2022, and is expected to register the highest CAGR during the forecast period. 

On the basis of application, the urinary fecal incontinence segment was the major shareholder in terms of revenue in 2022 and is expected to register the highest CAGR during the forecast period. 

Depending on end user, the hospitals segment garnered the largest share in terms of revenue in 2022, and is anticipated to register the highest CAGR during the forecast period. 

Region-wise, North America occupied the largest share in terms of revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. 

Overview

The sacral nerve stimulation market was valued at $422.66 million in 2022 and is estimated to reach $702.10 million by 2032, exhibiting a CAGR of 5.2% from 2023 to 2032. Sacral nerve stimulation is a clinical procedure used to treat certain situations associated with bladder and bowel dysfunction, consisting of urinary and fecal incontinence. It involves implantation of a small device, called a neurostimulator, which supplies electrical impulses to the sacral nerves located near the lower back. These sacral nerves are accountable for controlling the muscle tissues involved in bladder and bowel function.

During the sacral nerve stimulation procedure, the neurostimulator is typically implanted under the skin, often in the buttock area. Thin, insulated wires with electrodes at their tips, called leads, are then placed near the sacral nerves. Once the neurostimulator is activated, it delivers mild electrical signals to the sacral nerves, which modulate their activity. The electrical impulses sent by the neurostimulator help to regulate nerve signals, improve communication between the nerves and the bladder or bowel, and restore proper control over these functions. By stimulating the sacral nerves, sacral nerve stimulation aims to improve muscle coordination, reduce episodes of incontinence, and potentially alleviate symptoms of overactive bladder or fecal urgency. The major factors driving the growth of the sacral nerve stimulation market include increase in the number of populaces suffering from urological incontinence conditions, technological advancements in sacral nerve stimulation devices, and rise in adoption of sacral nerve stimulation devices. 

The rising overactive bladder or fecal urgency conditions can be debilitating, affecting an individual’s quality of life and thus, requiring long-term effective treatment. Sacral nerve stimulation devices have emerged as an effective treatment option for patients who have not responded to other traditional forms of therapy.

Furthermore, sacral nerve stimulation devices have undergone significant technological advancements, leading to smaller, flexible, and more effective devices. For example, newer devices are now compatible with MRI scans, eliminating the need for device removal during imaging procedures. Furthermore, introduction of rechargeable batteries and wireless capabilities enhances patient comfort and convenience. These technological advancements are anticipated to boost the demand for sacral nerve stimulation devices, as patients and physicians seek more efficient and user-friendly options. 

However, the high cost of sacral nerve stimulators and potential risks and complications associated with the procedure act as restraints to the market growth. The high upfront costs limit accessibility, particularly in regions with limited healthcare resources, while concerns about risks and complications are expected to deter potential patients and healthcare providers from adopting this therapy. 

Moreover, the global population is aging rapidly, and this demographic shift is expected to drive the demand for sacral nerve stimulation devices. As per the U.S. Census Bureau 2022, more than 56 million adults aged 65 and above live in the U.S., accounting for almost 16.9% of the nation’s population; thus, rise in geriatric population is anticipated to fuel the growth of the market. Furthermore, rise in demand of implantable stimulators owing to its advantages drives the market growth. Thus, the above factors are anticipated to fuel the market growth.

The sacral nerve stimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into devices and accessories. On the basis of application, it is categorized into urinary fecal incontinence, chronic anal fissure, and others (overactive bladder syndrome, urinary frequency). On the basis of end user, it is segregated into hospitals, specialty clinics, and others (research centers, ambulatory surgical centers). Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global sacral nerve stimulation market are Medtronic Plc, Beijing PINS Medical Co., Ltd., Saluda Medical Pty Ltd., and Axonics, Inc. The key players have adopted strategies such as acquisition, product launch, and product approval to expand their product portfolio.

 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sacral nerve stimulation market analysis from 2022 to 2032 to identify the prevailing sacral nerve stimulation market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the sacral nerve stimulation market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global sacral nerve stimulation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Regulatory Guidelines

● Additional company profiles with specific to client's interest

● Additional country or region analysis- market size and forecast

● Expanded list for Company Profiles

● Historic market data

● Key player details (including location, contact details, supplier/vendor network etc. in excel format)

● SWOT Analysis

Key Market Segments

○ Medtronic pl

Scope of Sacral Nerve Stimulation Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Moderate bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. Moderate bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of urological incontinence

3.4.1.2. Technological advancements in sacral nerve stimulation devices

3.4.1.3. Availability of medical reimbursement schemes

3.4.2. Restraints

3.4.2.1. High cost and side effects of Sacral nerve stimulation

3.4.3. Opportunities

3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Devices

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Accessories

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Urinary and Fecal Incontinence

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Chronic Anal Fissure

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Others

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Specialty Clinics

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Others

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by Product

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Market size and forecast, by Product

7.2.5.1.2. Market size and forecast, by Application

7.2.5.1.3. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Market size and forecast, by Product

7.2.5.2.2. Market size and forecast, by Application

7.2.5.2.3. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Market size and forecast, by Product

7.2.5.3.2. Market size and forecast, by Application

7.2.5.3.3. Market size and forecast, by End User

7.3. Europe

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by Product

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Market size and forecast, by Product

7.3.5.1.2. Market size and forecast, by Application

7.3.5.1.3. Market size and forecast, by End User

7.3.5.2. France

7.3.5.2.1. Market size and forecast, by Product

7.3.5.2.2. Market size and forecast, by Application

7.3.5.2.3. Market size and forecast, by End User

7.3.5.3. UK

7.3.5.3.1. Market size and forecast, by Product

7.3.5.3.2. Market size and forecast, by Application

7.3.5.3.3. Market size and forecast, by End User

7.3.5.4. Italy

7.3.5.4.1. Market size and forecast, by Product

7.3.5.4.2. Market size and forecast, by Application

7.3.5.4.3. Market size and forecast, by End User

7.3.5.5. Spain

7.3.5.5.1. Market size and forecast, by Product

7.3.5.5.2. Market size and forecast, by Application

7.3.5.5.3. Market size and forecast, by End User

7.3.5.6. Rest of Europe

7.3.5.6.1. Market size and forecast, by Product

7.3.5.6.2. Market size and forecast, by Application

7.3.5.6.3. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by Product

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Market size and forecast, by Product

7.4.5.1.2. Market size and forecast, by Application

7.4.5.1.3. Market size and forecast, by End User

7.4.5.2. China

7.4.5.2.1. Market size and forecast, by Product

7.4.5.2.2. Market size and forecast, by Application

7.4.5.2.3. Market size and forecast, by End User

7.4.5.3. Australia

7.4.5.3.1. Market size and forecast, by Product

7.4.5.3.2. Market size and forecast, by Application

7.4.5.3.3. Market size and forecast, by End User

7.4.5.4. India

7.4.5.4.1. Market size and forecast, by Product

7.4.5.4.2. Market size and forecast, by Application

7.4.5.4.3. Market size and forecast, by End User

7.4.5.5. South Korea

7.4.5.5.1. Market size and forecast, by Product

7.4.5.5.2. Market size and forecast, by Application

7.4.5.5.3. Market size and forecast, by End User

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Market size and forecast, by Product

7.4.5.6.2. Market size and forecast, by Application

7.4.5.6.3. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key market trends, growth factors and opportunities

7.5.2. Market size and forecast, by Product

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Market size and forecast, by Product

7.5.5.1.2. Market size and forecast, by Application

7.5.5.1.3. Market size and forecast, by End User

7.5.5.2. Saudi Arabia

7.5.5.2.1. Market size and forecast, by Product

7.5.5.2.2. Market size and forecast, by Application

7.5.5.2.3. Market size and forecast, by End User

7.5.5.3. South Africa

7.5.5.3.1. Market size and forecast, by Product

7.5.5.3.2. Market size and forecast, by Application

7.5.5.3.3. Market size and forecast, by End User

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Market size and forecast, by Product

7.5.5.4.2. Market size and forecast, by Application

7.5.5.4.3. Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Medtronic plc

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.0. Key strategic moves and developments

9.2. Beijing PINS Medical Co., Ltd.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.3. Axonics, Inc.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.0. Key strategic moves and developments

9.4. Saluda Medical Pty Ltd.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfoli

LIST OF TABLES

TABLE 01. GLOBAL SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 02. SACRAL NERVE STIMULATION MARKET FOR DEVICES, BY REGION, 2022-2032 ($MILLION)

TABLE 03. SACRAL NERVE STIMULATION MARKET FOR ACCESSORIES, BY REGION, 2022-2032 ($MILLION)

TABLE 04. GLOBAL SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 05. SACRAL NERVE STIMULATION MARKET FOR URINARY AND FECAL INCONTINENCE, BY REGION, 2022-2032 ($MILLION)

TABLE 06. SACRAL NERVE STIMULATION MARKET FOR CHRONIC ANAL FISSURE, BY REGION, 2022-2032 ($MILLION)

TABLE 07. SACRAL NERVE STIMULATION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. GLOBAL SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 09. SACRAL NERVE STIMULATION MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)

TABLE 10. SACRAL NERVE STIMULATION MARKET FOR SPECIALTY CLINICS, BY REGION, 2022-2032 ($MILLION)

TABLE 11. SACRAL NERVE STIMULATION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 12. SACRAL NERVE STIMULATION MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 13. NORTH AMERICA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 14. NORTH AMERICA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 17. U.S. SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 18. U.S. SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 19. U.S. SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 20. CANADA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 21. CANADA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 22. CANADA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 23. MEXICO SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 24. MEXICO SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 25. MEXICO SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 26. EUROPE SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 27. EUROPE SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 28. EUROPE SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 29. EUROPE SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 30. GERMANY SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 31. GERMANY SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 32. GERMANY SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 33. FRANCE SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 34. FRANCE SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 35. FRANCE SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 36. UK SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 37. UK SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 38. UK SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 39. ITALY SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 40. ITALY SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 41. ITALY SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 42. SPAIN SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 43. SPAIN SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 44. SPAIN SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 45. REST OF EUROPE SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 46. REST OF EUROPE SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 48. ASIA-PACIFIC SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 49. ASIA-PACIFIC SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 52. JAPAN SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 53. JAPAN SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 54. JAPAN SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 55. CHINA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 56. CHINA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 57. CHINA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 58. AUSTRALIA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 59. AUSTRALIA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 60. AUSTRALIA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 61. INDIA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 62. INDIA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 63. INDIA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 64. SOUTH KOREA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 65. SOUTH KOREA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 67. REST OF ASIA-PACIFIC SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 70. LAMEA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 71. LAMEA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 72. LAMEA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 73. LAMEA SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 74. BRAZIL SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 75. BRAZIL SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 76. BRAZIL SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 77. SAUDI ARABIA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 78. SAUDI ARABIA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 80. SOUTH AFRICA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 81. SOUTH AFRICA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 83. REST OF LAMEA SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 84. REST OF LAMEA SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA SACRAL NERVE STIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 86. MEDTRONIC PLC: KEY EXECUTIVES

TABLE 87. MEDTRONIC PLC: COMPANY SNAPSHOT

TABLE 88. MEDTRONIC PLC: PRODUCT SEGMENTS

TABLE 89. MEDTRONIC PLC: PRODUCT PORTFOLIO

TABLE 90. MEDTRONIC PLC: KEY STRATERGIES

TABLE 91. BEIJING PINS MEDICAL CO., LTD.: KEY EXECUTIVES

TABLE 92. BEIJING PINS MEDICAL CO., LTD.: COMPANY SNAPSHOT

TABLE 93. BEIJING PINS MEDICAL CO., LTD.: PRODUCT SEGMENTS

TABLE 94. BEIJING PINS MEDICAL CO., LTD.: PRODUCT PORTFOLIO

TABLE 95. AXONICS, INC.: KEY EXECUTIVES

TABLE 96. AXONICS, INC.: COMPANY SNAPSHOT

TABLE 97. AXONICS, INC.: PRODUCT SEGMENTS

TABLE 98. AXONICS, INC.: PRODUCT PORTFOLIO

TABLE 99. AXONICS, INC.: KEY STRATERGIES

TABLE 100. SALUDA MEDICAL PTY LTD.: KEY EXECUTIVES

TABLE 101. SALUDA MEDICAL PTY LTD.: COMPANY SNAPSHOT

TABLE 102. SALUDA MEDICAL PTY LTD.: PRODUCT SEGMENTS

TABLE 103. SALUDA MEDICAL PTY LTD.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. SACRAL NERVE STIMULATION MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF SACRAL NERVE STIMULATION MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN SACRAL NERVE STIMULATION MARKET (2023-2032)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW THREAT OF NEW ENTRANTS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. MODERATE INTENSITY OF RIVALRY

FIGURE 08. MODERATE BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL SACRAL NERVE STIMULATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. SACRAL NERVE STIMULATION MARKET, BY PRODUCT, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SACRAL NERVE STIMULATION MARKET FOR DEVICES, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF SACRAL NERVE STIMULATION MARKET FOR ACCESSORIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2022(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF SACRAL NERVE STIMULATION MARKET FOR URINARY AND FECAL INCONTINENCE, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF SACRAL NERVE STIMULATION MARKET FOR CHRONIC ANAL FISSURE, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF SACRAL NERVE STIMULATION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. SACRAL NERVE STIMULATION MARKET, BY END USER, 2022(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF SACRAL NERVE STIMULATION MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF SACRAL NERVE STIMULATION MARKET FOR SPECIALTY CLINICS, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF SACRAL NERVE STIMULATION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. SACRAL NERVE STIMULATION MARKET BY REGION, 2022(%)

FIGURE 22. U.S. SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 23. CANADA SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 24. MEXICO SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 25. GERMANY SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 26. FRANCE SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 27. UK SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 28. ITALY SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 29. SPAIN SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 30. REST OF EUROPE SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 31. JAPAN SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 32. CHINA SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 33. AUSTRALIA SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 34. INDIA SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 35. SOUTH KOREA SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 36. REST OF ASIA-PACIFIC SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 37. BRAZIL SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 38. SAUDI ARABIA SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 39. SOUTH AFRICA SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 40. REST OF LAMEA SACRAL NERVE STIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 41. TOP WINNING STRATEGIES, BY YEAR (2020-2023)

FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)

FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)

FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 45. COMPETITIVE DASHBOARD

FIGURE 46. COMPETITIVE HEATMAP: SACRAL NERVE STIMULATION MARKET

FIGURE 47. TOP PLAYER POSITIONING, 2022

FIGURE 48. MEDTRONIC PLC: NET SALES, 2020-2022 ($MILLION)

FIGURE 49. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 50. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 51. AXONICS, INC.: NET SALES, 2019-2021 ($MILLION)

FIGURE 52. AXONICS, INC.: REVENUE SHARE BY REGION, 2021 (%